The cost-utility of early use of high-flow nasal cannula in bronchiolitis

Springer Science and Business Media LLC - Tập 11 - Trang 1-8 - 2021
Jefferson Antonio Buendía1, Ranniery Acuña-Cordero2,3, Carlos E. Rodriguez-Martinez4
1Departamento de Farmacología y Toxicología, Facultad de Medicina, Grupo de Investigación en Farmacología y Toxicología, Universidad de Antioquia, Medellín, Colombia
2Departamento de Neumología Pediátrica, Hospital Militar Central, Bogotá, Colombia
3Departamento de Pediatría, Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá, Colombia
4Department of Pediatrics, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia

Tóm tắt

High-flow nasal cannula (HFNC) oxygen is a non-invasive ventilation system that was introduced as an alternative to CPAP (continuous positive airway pressure), with a marked increase in its use in pediatric care settings. This study aimed to evaluate the cost-effectiveness of early use of HFNC compared to oxygen by nasal cannula in an infant with bronchiolitis in the emergency setting. A decision tree model was used to estimate the cost-effectiveness of HFNC compared with oxygen by nasal cannula (control strategy) in an infant with bronchiolitis in the emergency setting. Cost data were obtained from a retrospective study on bronchiolitis from tertiary centers in Rionegro, Colombia, while utilities were collected from the literature. The QALYs per patient calculated in the base-case model were 0.9141 (95% CI 0.913–0.915) in the HFNC and 0.9105 (95% CI 0.910–0.911) in control group. The cost per patient was US$368 (95% CI US$ 323–411) in HFNC and US$441 (95% CI US$ 384–498) per patient in the control group. HFNC was cost-effective HFNC compared to oxygen by nasal cannula in an infant with bronchiolitis in the emergency setting. The use of this technology in emergency settings will allow a more efficient use of resources, especially in low-resource countries with high prevalence of bronchiolitis .

Tài liệu tham khảo

Manley BJ, Owen L, Doyle LW, Davis PG. High-flow nasal cannulae and nasal continuous positive airway pressure use in non-tertiary special care nurseries in Australia and New Zealand. J Paediatr Child Health. 2012;48(1):16–21. https://doi.org/10.1111/j.1440-1754.2011.02186.x.

Zielinska A, Jassem-Bobowicz JM, Kwiatkowska J. Oxygen therapy with high-flow nasal cannulas in children with acute bronchiolitis. Anaesthesiol Intensive Ther. 2019;51(1):51–5. https://doi.org/10.5603/AIT.2019.0010.

Joseph MM, Edwards A. Acute bronchiolitis: assessment and management in the emergency department. Pediatr Emerg Med Pract. 2019;16(10):1–24.

Mikalsen IB, Davis P, Oymar K. High flow nasal cannula in children: a literature review. Scand J Trauma Resusc Emerg Med. 2016;24(1):93. https://doi.org/10.1186/s13049-016-0278-4.

Hoffman E, Reichmuth KL, Cooke ML. A review of the use of high-flow nasal cannula oxygen therapy in hospitalised children at a regional hospital in the Cape Town metro. South Africa S Afr Med J. 2019;109(4):272–7. https://doi.org/10.7196/SAMJ.2019.v109i4.13145.

Hoffman SB, Terrell N, Driscoll CH, Davis NL. Impact of high-flow nasal cannula use on neonatal respiratory support patterns and length of stay. Respir Care. 2016;61(10):1299–304. https://doi.org/10.4187/respcare.04668.

Talamoni HL, Buendia JA, Pisapia ND, Sanchez AA, et al. Non-Invasive Ventilation in Patients Hospitalized with Severe Bronchiolitis. American Journal of Respiratory and Critical Care Medicine. 2015;191:A4762.

Lodeserto FJ, Lettich TM, Rezaie SR. High-flow nasal cannula: mechanisms of action and adult and pediatric indications. Cureus. 2018;10(11):e3639. https://doi.org/10.7759/cureus.3639.

Moreel L, Proesmans M. High flow nasal cannula as respiratory support in treating infant bronchiolitis: a systematic review. Eur J Pediatr. 2020;179(5):711–8. https://doi.org/10.1007/s00431-020-03637-0.

Wang J, Lee KP, Chong SL, Loi M, Lee JH. High flow nasal cannula in the emergency department: indications, safety and effectiveness. Expert Rev Med Devices. 2018;15(12):929–35. https://doi.org/10.1080/17434440.2018.1548276.

Slain KN, Shein SL, Rotta AT. The use of high-flow nasal cannula in the pediatric emergency department. J Pediatr. 2017;93(Suppl 1):36–45. https://doi.org/10.1016/j.jped.2017.06.006.

datos Ud. ¿Cuántas camas de UCI por persona hay en Colombia? El tiempo. 2020 28/03/2020.

Ferolla FM, Hijano DR, Acosta PL, Rodriguez A, Duenas K, Sancilio A, et al. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med. 2013;187(9):983–90. https://doi.org/10.1164/rccm.201301-0016OC.

Caballero MT, Polack FP. Respiratory syncytial virus is an "opportunistic" killer. Pediatr Pulmonol. 2018;53(5):664–7. https://doi.org/10.1002/ppul.23963.

Arraut PB, Lesmes, A.C. Caracterización de la población con bronquiolitis en la Clinica Infantil Colsubsidio en el año 2013 Universidad del Rosario2013. Available from: http://repository.urosario.edu.co/bitstream/handle/10336/10515/53106146-2015.pdf?sequence=1.

Pineros JG, Baquero H, Bastidas J, Garcia J, Ovalle O, Patino CM, et al. Respiratory syncytial virus infection as a cause of hospitalization in population under 1 year in Colombia. J Pediatr. 2013;89(6):544–8. https://doi.org/10.1016/j.jped.2013.04.002.

Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol (Madr). 2020;48(1):56–61. https://doi.org/10.1016/j.aller.2019.04.004.

Ávila García IA, Valero Garzón A, Pira Paredes LÁ, Socha Rodríguez JP. Factores de riesgo identificados en niños que ingresaron a la unidad de cuidado intensivo pediátrico por bronquiolitis severa en el hospital occidente de Kennedy durante julio de 2007 a junio de 2009 Bogota: Universidad Militar Nueva Granada; 2009 [150]. Available from: https://repository.unimilitar.edu.co/handle/10654/10335.

Rodriguez-Martinez CE, Sossa-Briceno MP, Nino G. Predictors of prolonged length of hospital stay for infants with bronchiolitis. J Investig Med. 2018;66(6):986–91. https://doi.org/10.1136/jim-2018-000708.

Rodriguez-Martinez CE, Sossa-Briceno MP. Castro-Rodriguez JA. Allergol Immunopathol (Madr): Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country; 2019.

Instituto, Nacional, Salud d. Infeccion respiratoria aguda en Colombia 2017 [05/07/2019]. Available from: https://www.ins.gov.co/buscador-eventos/Informesdeevento/Informe%20IRA%20Final%202017.pdf.

Buendia JA, Patino DG. Costs of Respiratory Syncytial Virus Hospitalizations in Colombia. Pharmacoecon Open. 2020.

Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018;378(12):1121–31. https://doi.org/10.1056/NEJMoa1714855.

Estadisticas DAN. Índice de Precios al Consumidor - IPC 2020. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-consumidor-ipc

la Bd, Republica. Tasa Representativa del Mercado (TRM - Peso por dólar) 2019. cited 2020. Available from: https://www.banrep.gov.co/es/estadisticas/trm.

Departamento, Nacional, (DANE) DE. Archivo Nacional de Datos 2019. Available from: https://sitios.dane.gov.co/anda-index/.

Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89(7):673–8. https://doi.org/10.1136/adc.2003.036129.

Sanchez-Luna M, Burgos-Pol R, Oyaguez I, Figueras-Aloy J, Sanchez-Solis M, Martinon-Torres F, et al. Cost-utility analysis of Palivizumab for respiratory syncytial virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis. 2017;17(1):687. https://doi.org/10.1186/s12879-017-2803-0.

Blanken MO, Frederix GW, Nibbelke EE, Koffijberg H, Sanders EAM, Rovers MM, et al. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. Eur J Pediatr. 2018;177(1):133–44. https://doi.org/10.1007/s00431-017-3046-1.

Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010;11(1):105–15. https://doi.org/10.1007/s10198-009-0206-x.

Jones S, Rantell K, Stevens K, Colwell B, Ratcliffe JR, Holland P, et al. Outcome at 6 months after admission for pediatric intensive care: a report of a national study of pediatric intensive care units in the United Kingdom. Pediatrics. 2006;118(5):2101–8. https://doi.org/10.1542/peds.2006-1455.

Meijboom MJ, Rozenbaum MH, Benedictus A, Luytjes W, Kneyber MC, Wilschut JC, et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in the Netherlands. Vaccine. 2012;30(31):4691–700. https://doi.org/10.1016/j.vaccine.2012.04.072.

Shiri T, Khan K, Keaney K, Mukherjee G, McCarthy ND, Petrou S. Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions. Value Health. 2019;22(11):1329–44. https://doi.org/10.1016/j.jval.2019.06.011.

Chiou CF, Weaver MR, Bell MA, Lee TA, Krieger JW. Development of the multi-attribute pediatric asthma health outcome measure (PAHOM). Int J Qual Health Care. 2005;17(1):23–30. https://doi.org/10.1093/intqhc/mzh086.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346(mar25 1):f1049. https://doi.org/10.1136/bmj.f1049.

Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Mak. 1998;18(1):95–109. https://doi.org/10.1177/0272989X9801800117.

Kepreotes E, Whitehead B, Attia J, Oldmeadow C, Collison A, Searles A, et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial. Lancet. 2017;389(10072):930–9. https://doi.org/10.1016/S0140-6736(17)30061-2.

Vahlkvist S, Jurgensen L, la Cour A, Markoew S, Petersen TH, Kofoed PE. High flow nasal cannula and continuous positive airway pressure therapy in treatment of viral bronchiolitis: a randomized clinical trial. Eur J Pediatr. 2020;179(3):513–8. https://doi.org/10.1007/s00431-019-03533-2.

Ergul AB, Caliskan E, Samsa H, Gokcek I, Kaya A, Zararsiz GE, et al. Using a high-flow nasal cannula provides superior results to OxyMask delivery in moderate to severe bronchiolitis: a randomized controlled study. Eur J Pediatr. 2018;177(8):1299–307. https://doi.org/10.1007/s00431-018-3191-1.

Bassiouny MR, Gupta A, el Bualy M. Nasal continuous positive airway pressure in the treatment of respiratory distress syndrome: an experience from a developing country. J Trop Pediatr. 1994;40(6):341–4. https://doi.org/10.1093/tropej/40.6.341.

Monteverde E, Fernandez A, Ferrero F, Barbaro C, De Lillo L, Lavitola M, et al. High-flow nasal cannula oxygen therapy in infants with acute lower respiratory tract infection. An experience in hospitals of the City of Buenos Aires. Arch Argent Pediatr. 2019;117(5):286–93. https://doi.org/10.5546/aap.2019.eng.286.

Buendia JA. Attitudes, knowledge and beliefs of patient about anti-hypertensive drugs. Biomedica. 2012;32(4):578–84. https://doi.org/10.1590/S0120-41572012000400013.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 11

1-8

Thông tin tác giả